New York, NY, United States of America

Xinlei Chen

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignees: Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xinlei Chen. Retrieved from https://idiyas.com/inventor/xinlei-chen-8b7rvi6d

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Inventor Xinlei Chen

Introduction

Xinlei Chen is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of immunology, particularly in the development of targeted therapies for cancer. His work focuses on innovative approaches to combat DLL3-associated cancers.

Latest Patents

Xinlei Chen holds a patent for "DLL3-targeting antibodies and uses thereof." This patent relates to immunoglobulin-related compositions, such as antibodies or antigen-binding fragments that can bind to delta-like protein 3 (DLL3). The antibodies developed through this technology are useful in methods for detecting and treating DLL3-associated cancers in subjects in need.

Career Highlights

Throughout his career, Xinlei Chen has worked with esteemed institutions, including Memorial Sloan Kettering Cancer Center and the Tri-Institutional Therapeutics Discovery Institute. His experience in these organizations has allowed him to contribute to groundbreaking research and advancements in cancer treatment.

Collaborations

Xinlei Chen has collaborated with notable colleagues, including John Poirier and Charles Rudin. These partnerships have fostered a collaborative environment that enhances the development of innovative cancer therapies.

Conclusion

Xinlei Chen's work in developing DLL3-targeting antibodies represents a significant advancement in cancer treatment. His contributions to immunology and collaboration with leading institutions highlight his commitment to improving patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…